BSR_05_0025_A4_S57
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.410
- WNT_BETA_CATENIN_SIGNALING+0.390
- UV_RESPONSE_DN+0.340
- HEDGEHOG_SIGNALING+0.300
- HYPOXIA+0.240
- KRAS_SIGNALING_DN+0.220
- NOTCH_SIGNALING+0.220
- MYOGENESIS+0.210
- APICAL_SURFACE+0.190
- KRAS_SIGNALING_UP+0.190
Top 10 suppressed
- E2F_TARGETS-0.550
- MTORC1_SIGNALING-0.480
- G2M_CHECKPOINT-0.470
- MYC_TARGETS_V2-0.430
- OXIDATIVE_PHOSPHORYLATION-0.410
- INTERFERON_ALPHA_RESPONSE-0.380
- MYC_TARGETS_V1-0.370
- DNA_REPAIR-0.350
- PI3K_AKT_MTOR_SIGNALING-0.300
- UNFOLDED_PROTEIN_RESPONSE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AC-A2FK-01A-12R-A180-07 | — | A | 0.896 |
| 2 | TCGA-BH-A28O-01A-11R-A22K-07 | — | A | 0.889 |
| 3 | TCGA-AR-A2LN-01A-21R-A18M-07 | — | A | 0.880 |
| 4 | TCGA-A7-A4SC-01A-12R-A266-07 | — | A | 0.880 |
| 5 | TCGA-BH-A0EA-01A-11R-A115-07 | — | A | 0.877 |
| 6 | TCGA-A2-A4RY-01A-31R-A266-07 | — | A | 0.876 |
| 7 | SRR35579834 | — | A | 0.867 |
| 8 | MBCProject_7544_T2_RNA | — | A | 0.862 |
| 9 | TCGA-A2-A1G6-01A-11R-A13Q-07 | — | A | 0.861 |
| 10 | SRR8613732 | — | A | 0.859 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.410 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.390 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| HYPOXIA | 0.240 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |
| APICAL_JUNCTION | 0.140 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.140 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.140 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.070 | Idelalisib | — uncovered |
| COAGULATION | 0.030 | Binimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.020 | Inavolisib | — uncovered |
| APOPTOSIS | 0.020 | Idelalisib | — uncovered |